Genincode PLC

GENIG.UK

$0.07

Closing

▲0.88%

1D

▲8.57%

YTD

GENIG

BBG011WG2CV2

Market cap

$13.03M

52 week high

$0.18

52 week low

$0.04

Volume

59,614

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$13.03M

Analysts' Rating

STRONG BUY

Price Target (Mean)

Unable to collect data for some field(s).

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

-

52 week high

$0.18

52 week low

$0.04

Div. Yield

%

EPS Annual Growth

0.00

Company Profile

GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company’s product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.